Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma

The purpose of this study is to assess the efficacy and safety profile of lanreotide (a somatostatin analog) in patients with advanced/metastatic pheochromocytoma or paraganglioma. You are being asked to participate in this study because you have metastatic pheochromocytoma or metastatic paraganglioma and you have never been treated with a somatostatin analogs. Taking part in this study may or may not make your health better. Approximately 40 individuals will be asked to participate in this study.

Are you Eligible? (Inclusion Criteria)

• Are you at least 18 years of age?
• Do you have diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability?
• Do you have life expectancy of greater than 12 weeks?